A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Nowotwór B-komórkowy (chłoniak lub białaczka) potwierdzona badaniem histologicznym
- •Choroba nawrotowa, postępująca lub oporna na leczenie - po co najmniej 2 poprzednich metodach leczenia
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (skala ECOG ≤ 2)
✗ Disqualifies
- •Inne typy nowotworów niż wymienione w kryteriach włączenia
- •Zajęcie centralnego układu nerwowego lub przeszkody w jego funkcjonowaniu
- •Historia przeszczepów szpiku lub terapii komórkowej w ostatnich 3 miesiącach
- •Poprzednie ciężkie reakcje zapalne na podobne leczenie
- •Aktywne, niekontrolowane infekcje
- •Niepowstrzymane skutki uboczne z wcześniejszego leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (31)
Research Site
La Jolla, United States
Research Site
Boston, United States
Research Site
Rochester, United States
Research Site
Hackensack, United States
Research Site
New York, United States
Research Site
New York, United States
Research Site
Charlotte, United States
Research Site
Winston-Salem, United States
Research Site
Houston, United States
Research Site
Seattle, United States
Research Site
Melbourne, Australia
Research Site
Nedlands, Australia
Research Site
Calgary, Canada
Research Site
Toronto, Canada
Research Site
Montreal, Canada
Research Site
Hangzhou, China
Research Site
Shanghai, China
Research Site
København Ø, Denmark
Research Site
Pessac, France
Research Site
Villejuif, France
Research Site
Göttingen, Germany
Research Site
München, Germany
Research Site
Ulm, Germany
Research Site
Würzburg, Germany
Research Site
Bologna, Italy
Research Site
Milan, Italy
Research Site
Chūōku, Japan
Research Site
Kashiwa, Japan
Research Site
Barcelona, Spain
Research Site
L'Hospitalet de Llobregat, Spain
Research Site
Madrid, Spain
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.